Depth - Treat The Skin's Foundation
Tissue laxity is largely the result of structural weakening in the skin’s foundation (SMAS/Platysma) at ~4.5mm deep. Prior to Ultherapy, this layer was only accessible during a surgical facelift, since non-invasive modalities, such as lasers and radio-frequency, are limited to treating the dermis (< 3mm). The Ulthera® System is the only technology that non-invasively treats at a 3 discrete depth (1.5mm, 3mm and 4.5mm), to target both the dermis and the foundational tissue layers where laxity begins.
Temperature - Optimized Neocollagenesis
Clinical studies demonstrate that collagen contraction and denaturation are optimized at temperatures between 60-70°C. The Ulthera® System is the only device that reaches these optimized temperatures at depth, without heating the skin’s surface. The ultrasound energy is micro-focused to a point below the skin’s surface, causing cellular friction and heating tissue to ~65°C. This heat causes collagen contraction and denaturation and initiates aggressive collagen synthesis.
Precision - Surgical Precison Without An Incision
Precise energy delivery increases the consistency and safety of treatment. Lasers are precise, but only treat the superficial skin layers. Radio-frequency reaches deeper than lasers, but imprecisely bulk heats tissue at variable temperatures and depths. Only Ultherapy precisely heats tissue at a specific depth and temperature, with spacing between each thermal injury to promote healing. Real-time ultrasound imaging lets clinicians see exactly where energy will be delivered, providing an added level of precision to the procedure.
Imaging -The ONLY "See & Treat" Technology
The Ulthera® System is the only non-invasive device that allows clinicians to see where they’re treating. Using Ulthera’s patented DeepSEE® technology, the system provides real-time ultrasound visualization of the skin down to 8mm. A treatment line is superimposed over this image to show where energy will be delivered. This “See & Treat” technology lets clinicians verify energy is being delivered at the correct tissue depth and avoid sub-dermal structures such as bone. Other non-invasive devices, including radio-frequency, force clinicians to essentially treat “blind”. The Ulthera System has an FDA-indication specific to ultrasound visualization of dermal and sub-dermal tissue layers.